News for Patients with Small Cell Lung Cancer - New FDA Approval (January 2019 – Article)

The FDA has approved the use of nivolumab (Opdivo) in patients with advanced small cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy and at least one other line of therapy. This represents the first new medication for the treatment of SCLC in 20 years and is the first and only immunotherapy drug currently approved for use in these patients.

Thank you for your participation in the Bonnie J. Addario Lung Cancer Registry! This month, we are pleased to share exciting updates and opportunities within the Lung Cancer Registry and the greater cancer communities:

The FDA has approved the use of nivolumab (Opdivo) in patients with advanced small cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy and at least one other line of therapy. This represents the first new medication for the treatment of SCLC in 20 years and is the first and only immunotherapy drug currently approved for use in these patients.

Read more from the ASCO Post

Thank you for your time and ongoing support of the Lung Cancer Registry. Your participation and willingness to share your health history will improve your own life as well as the lives of many others.

Together we can make a difference as we continue the fight to end lung cancer.

Sandra Shaw
Director, Patient Registry
Bonnie J. Addario Lung Cancer Foundation
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.lungcancerregistry.org